Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Laquinimod interferes with migratory capacity of T cells and reduces IL-17 levels, inflammatory demyelination and acute axonal damage in mice with experimental autoimmune encephalomyelitis.
Targeted ablation of oligodendrocytes induces axonal pathology independent of overt demyelination.
Glatiramer acetate (copaxone) modulates platelet activation and inhibits thrombin-induced calcium influx: possible role of copaxone in targeting platelets during autoimmune neuroinflammation.
Mycoplasma pneumonia seroposivity in Iranian patients with relapsing-remitting multipl sclerosis: a randomized case-control study.
Calcitriol Modulates the CD46 Pathway in T Cells.
Clinical overview of the seizure risk of dalfampridine.
Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial.
Long term lymphocyte reconstitution after alemtuzumab treatment of multiple sclerosis.
Pharmacokinetic profile of dalfampridine extended release: clinical relevance in patients with MS.
Blockade of the High-Affinity Interleukin-2 Receptors with Daclizumab High-Yield Process: Pharmacokinetic/Pharmacodynamic Analysis of Single- and Multiple-Dose Phase I Trials.
Gilenya prescribing information
Mapi Pharma Receives Additional Claims for Its U.S. Patent for Glatiramer Acetate Depot for the Treatment of Multiple Sclerosis
Modulation of nitric oxide synthase by arginase and methylated arginines during the acute phase of experimental multiple sclerosis.
Sodium channels contribute to microglia/macrophage activation and function in EAE and MS.
Pharmacokinetics of fingolimod (FTY720) and a combined oral contraceptive coadministered in healthy women: drug-drug interaction study results.
Double Blind Combination of Rituximab by Intravenous and Intrathecal Injection Versus Placebo in Patients With Low-Inflammatory Secondary Progressive Multiple Sclerosis (RIVITaLISe)
Amyloid precursor protein at node of Ranvier modulates nodal formation.
First reported case of diabetes mellitus type 1 as a possible secondary autoimmune disease following alemtuzumab treatment in MS.
Plasma Exchange in a Patient with Tumefactive, Corticosteroid-Resistant Multiple Sclerosis.
Efficacy and safety of Privigen(®) in patients with chronic inflammatory demyelinating polyneuropathy: results of a prospective, single-arm, open-label Phase III study (the PRIMA study).
B-cell depletion in vitro and in vivo with an afucosylated anti-CD19 antibody.
Neuroimmune Crosstalk in CNS Disorders: The Histamine Connection.
Rituximab: Don't Count It Out as MS Treatment
Assessment of the effect of interferon-beta1a therapy on thyroid and salivary gland functions in patients with multiple sclerosis using quantitative salivary gland scintigraphyz.
Teva Presents New Data Which Demonstrate Reduction of Injection-Related Adverse Events with the Less Frequent Dosing of Three-times-a-week COPAXONE® (glatiramer acetate injection) 40 mg Compared to Daily COPAXONE® 20 mg

Pages